BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38858293)

  • 21. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
    Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
    Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant chemoradiotherapy improves histological results compared with perioperative chemotherapy in locally advanced esophageal adenocarcinoma.
    Luc G; Vendrely V; Terrebonne E; Chiche L; Collet D
    Ann Surg Oncol; 2015 Feb; 22(2):604-9. PubMed ID: 25169119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
    Hoeppner J; Lordick F; Brunner T; Glatz T; Bronsert P; Röthling N; Schmoor C; Lorenz D; Ell C; Hopt UT; Siewert JR
    BMC Cancer; 2016 Jul; 16():503. PubMed ID: 27435280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma.
    Chao L; Liu J; Chen Y; Fan Y; Guo S; Zhang S
    Thorac Cancer; 2024 Mar; 15(8):622-629. PubMed ID: 38316630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel-Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15-Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network.
    Tankel J; Ahmed N; Mueller C; Najmeh S; Spicer J; Mulder D; Cool-Lartigue J; Rousseau M; Frechette D; Sud S; Kavan P; Moghrabi A; Champagne M; Lemay F; Dalfen R; Sirhan S; Asselah J; Alcindor T; Ferri L
    Ann Surg Oncol; 2024 Apr; 31(4):2461-2469. PubMed ID: 38142255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant Strategies for Esophageal Cancer: Role of Immunotherapy and Positron emission tomography (PET)-Guided Strategies.
    Barron CC; Wang X; Elimova E
    Thorac Surg Clin; 2023 May; 33(2):197-208. PubMed ID: 37045489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).
    Stahl M; Maderer A; Lordick F; Mihaljevic AL; Kanzler S; Hoehler T; Thuss-Patience P; Mönig S; Kunzmann V; Schroll S; Sandermann A; Tannapfel A; Meyer HJ; Schuhmacher C; Wilke H; Moehler M;
    Eur J Cancer; 2018 Apr; 93():119-126. PubMed ID: 29501977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer.
    Narumiya K; Metzger R; Bollschweiler E; Alakus H; Brabender J; Drebber U; Hölscher AH; Warnecke-Eberz U
    Pharmacogenomics; 2011 Feb; 12(2):205-14. PubMed ID: 21332314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment.
    Ganschow P; Hofmann L; Stintzing S; Heinemann V; Angele M; Werner J; Schulz C
    J Gastrointest Surg; 2021 Jan; 25(1):58-66. PubMed ID: 32040809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant and adjuvant therapy in esophageal cancer.
    Weiss JA; Jain S
    J Gastrointest Oncol; 2023 Aug; 14(4):1927-1932. PubMed ID: 37720447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term outcome of Ivor Lewis esophagectomy following neoadjuvant chemoradiation versus perioperative chemotherapy in patients with locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: a propensity score-matched analysis.
    Plum PS; Damanakis A; Buschmann L; Ernst A; Datta RR; Schiffmann LM; Zander T; Fuchs H; Chon SH; Alakus H; Schröder W; Hölscher AH; Bruns CJ; Bludau M
    J Cancer Res Clin Oncol; 2022 May; 148(5):1223-1234. PubMed ID: 34223965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Placement of fully covered self-expandable metal stents in patients with locally advanced esophageal cancer before neoadjuvant therapy.
    Siddiqui AA; Sarkar A; Beltz S; Lewis J; Loren D; Kowalski T; Fang J; Hilden K; Adler DG
    Gastrointest Endosc; 2012 Jul; 76(1):44-51. PubMed ID: 22726465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor differentiation impacts response to neoadjuvant therapy and survival in patients with esophageal adenocarcinoma.
    McKay SC; Louie BE; Molena D; Andrews WG; Boerner T; Hofstetter WL; Yeung J; Darling GE; Sharata A; Peyre CG; Dunn C; Lipham JC; Marginean H; DeMeester SR
    J Thorac Cardiovasc Surg; 2024 Jun; 167(6):1943-1950. PubMed ID: 37788788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Predictors of Locally Advanced Pathology in Esophageal Adenocarcinoma.
    Gomez Cifuentes JD; Haider M; Sanaka MR; Kumar P; Bena J; McMichael J; Sohal DP; Raja S; Murthy S; Thota PN
    Cureus; 2021 Oct; 13(10):e18991. PubMed ID: 34820244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
    He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
    Front Immunol; 2022; 13():853922. PubMed ID: 35720312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
    Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
    Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
    Depypere L; Thomas M; Moons J; Coosemans W; Lerut T; Prenen H; Haustermans K; Van Veer H; Nafteux P
    World J Surg Oncol; 2019 May; 17(1):89. PubMed ID: 31133018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis.
    Liang Z; Chen T; Li W; Lai H; Li L; Wu J; Zhang H; Fang C
    Medicine (Baltimore); 2024 Jan; 103(3):e36785. PubMed ID: 38241577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Esophageal Cancer: New Insights into a Heterogenous Disease.
    Krug S; Michl P
    Digestion; 2017; 95(4):253-261. PubMed ID: 28384630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current preoperative and perioperative concepts in tumor treatment for locally advanced esophageal carcinoma from a surgical perspective].
    Hoeppner J
    Chirurg; 2021 Dec; 92(12):1094-1099. PubMed ID: 34387699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.